A possible way to clarify this issue could be by assessing the PR expression in fallopian tube cells from ovariectomies of risk subjects [for examples patients with a Breast Cancer Gene (BRCA) mutation] and comparing them with healthy controls. The gene discussed is PGR; the disease is breast cancer.